25 completed, 8 unknown, 3 not yet recruiting, 2 withdrawn. 33 Phase 1, 3 Phase 4, 2 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 33 | Completed 21, Unknown 8, Not yet recruiting 3, Active not recruiting 1 |
| Phase 4 | 3 | Withdrawn 2, Completed 1 |
| Not applicable | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Reference Drug: new trials by email Literature Review of Reference Drug trials Research Report on Reference Drug
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers Test Drug, Reference Drug - Hypercholerolemia, Dyslipidemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 61 | 2026-08-06 | 2026-09-09 |
| Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fed Conditions Test Drug, Reference Drug - Moderate-to-severe Benign Prostatic Hyperplasia (BPH) | Phase 1 | Not yet recruiting | AJU Pharm Co., Ltd. | 36 | 2026-07-01 | 2026-06-11 |
| Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting Conditions Test Drug, Reference Drug - Moderate-to-severe Benign Prostatic Hyperplasia (BPH) | Phase 1 | Completed | AJU Pharm Co., Ltd. | 45 | 2026-06-27 | 2026-09-21 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults Test Drug, Reference Drug - Hypercholesterolemia, Dyslipidemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 41 | 2026-06-11 | 2026-07-10 |
| Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer CKD-215, D215 - Ovarian Cancer | Phase 1 | Not yet recruiting | Chong Kun Dang Pharmaceutical | 24 | 2026-06-01 | 2026-04-15 |
| Efficacy and Safety Evaluation of SMO1 in Patients With Retinal Vein Occlusive Macular Edema Reference Drug, SMO1 - Retinal Vein Occlusion With Macular Edema | Phase 3 | Recruiting | SANGMYUNG innovation | 312 | 2026-01-29 | 2026-07-16 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C714 and C714R in Healthy Adults Test Drug, Reference Drug - Dyslipidemia | Phase 1 | Active not recruiting | AJU Pharm Co., Ltd. | 60 | 2025-05-24 | 2025-06-12 |
| Initial Pilot Study to Evaluate the Safety and Temporary Symptom Improvement Efficacy of CKD-981 CKD-981(1), CKD-981(2), Sham device - Knee Osteoarthritis | Phase 2 | Completed | Chong Kun Dang Pharmaceutical | 100 | 2025-04-28 | 2026-04-13 |
| A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A AD-120A, AD-120 - Gastroesophageal Reflux Disease (GERD) | Phase 1 | Not yet recruiting | Addpharma Inc. | 48 | 2025-04-21 | 2025-04-08 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults Test Drug, Reference Drug - Hypercholesterolemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 60 | 2025-03-29 | 2025-06-12 |
| A Study to Compare Eutropin Formulations in Healthy Volunteers for Bioavailability, Safety, and Tolerability Test Drug (Eutropin Catridge, 48IU/Cartridge), Reference Drug (Eutropin, 4 IU/vial) - Healthy Volunteers | Phase 1 | Completed | LG Chem | 48 | 2025-01-13 | 2025-04-17 |
| Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics Vamorolone, Midazolam - Drug Interaction | Phase 1 | Completed | Santhera Pharmaceuticals | 18 | 2024-08-13 | 2025-12-15 |
| Bioequivalence Study of Rosuvastatin Tablet Test Drug, Reference Drug - Healthy Individuals | Not applicable | Completed | University of Karachi | 36 | 2022-11-24 | 2023-03-22 |
| A Study to Compare PK, PD and Safety of the AD-214 and AD-2141 AD-214, AD-2141 - Gastroesophageal Reflux Disease | Phase 1 | Completed | Addpharma Inc. | 41 | 2021-11-01 | 2022-07-20 |
| A Clinical Trial to Compare the Pharmacokinetics and Safety of "BR1016C" With "BR1016D" in Healthy Volunteers BR1016C, BR1016D - Chronic Heart Failure | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 60 | 2021-10-27 | 2023-05-24 |
| A Clinical Trial to Compare the Pharmacokinetics and Safety of "BR1016A" With "BR1016B" in Healthy Volunteers BR1016A, BR1016B - Chronic Heart Failure | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 60 | 2021-10-22 | 2023-05-24 |
| A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52L in Healthy Volunteers C52R1H Tab. and C52R2 Tab., AJU-C52L - Hypertension | Phase 1 | Unknown | AJU Pharm Co., Ltd. | 60 | 2021-09-24 | 2021-10-14 |
| A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52H in Healthy Volunteers C52R1M Tab. and C52R2 Tab., AJU-C52H - Hypertension | Phase 1 | Unknown | AJU Pharm Co., Ltd. | 60 | 2021-09-17 | 2021-10-14 |
| A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers Lixiana(D006), CKD-344 - Anticoagulant | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 60 | 2021-04-27 | 2021-04-30 |
| A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects Rabeprazole Sodium 10mg, Rabeprazole Sodium 20mg - Gastroesophageal Reflux Disease | Phase 1 | Completed | Yungjin Pharm. Co., Ltd. | 88 | 2021-01-13 | 2024-01-24 |
Showing 20 of 40. Sign in to see all of them.
Cardiovascular Diseases (5) · Dyslipidemias (4) · Gastroesophageal Reflux (4) · Hypertension (3) · Diabetes Mellitus, Type 2 (2) · Hypercholesterolemia (2) · Gastritis (1) · Hyperlipidemias (1) · Hypogonadism (1) · Osteoarthritis, Knee (1) · Ovarian Neoplasms (1)
Chong Kun Dang Pharmaceutical (13) · AJU Pharm Co., Ltd. (9) · Pfizer (5) · Addpharma Inc. (4) · Boryung Pharmaceutical Co., Ltd (2) · Atabay Kimya Sanayi Ticaret A.S. (1) · Geropharm (1) · LG Chem (1) · SANGMYUNG innovation (1) · Santhera Pharmaceuticals (1) · University of Karachi (1) · Yungjin Pharm. Co., Ltd. (1)
South Korea (31) · Brazil (2) · Germany (1) · Pakistan (1) · Russia (1) · Turkey (Türkiye) (1)
Min-gul Kim (4) · Min-gi Kim (2) · Seunghwan Lee, M.D.,Ph.D (2) · Yook-Hwan Noh (2) · An-Hye Kim, M.D., PhD. (1) · Chang-Min Seong (1) · Hyewon Chung, M.D., PhD. (1) · In-Jin Jang, M.D.,Ph.D (1) · Jang Hee Hong (1) · Jeong-Yeol Park, Ph.D (1) · Michael Lissy, MD (1) · Min-gul Kim, M.D., PhD. (1) · Muhammad Raza Shah, PhD (1) · Muradiye Nacak, MD,PhD (1)